ALS meds safety profiles
Researchers compared safety signals for riluzole, edaravone, and tofersen in ALS using adverse event data from the Food and Drug Administration (2009–2024). Riluzole linked to abdominal discomfort and liver enzyme changes; edaravone to falls and gait disturbance; tofersen to headaches and red blood cells in cerebrospinal fluid. Thrombosis was a shared serious risk; targets like F10 and MMP9 were noted.
Research#Amyotrophic Lateral Sclerosis (ALS)#Motor Neurone Disease (MND)